Anzeige
❌
Mehr »
Donnerstag, 19.11.2026 - Börsentäglich über 12.000 News
Rund 40 Mio. USD Staatsaufträge bis Juni 2029 gebucht: Jetzt zählt die Marge!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
OP

WKN: A3DVNM | ISIN: FR001400CM63 | Ticker: ZR8
Stuttgart
19.11.26 | 16:18
0,241 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ONCODESIGN PRECISION MEDICINE SA Chart 1 Jahr
5-Tage-Chart
ONCODESIGN PRECISION MEDICINE SA 5-Tage-Chart
RealtimeGeldBriefZeit
0,2330,26116:37

Aktuelle News zur ONCODESIGN PRECISION MEDICINE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
22.10.Oncodesign Precision Medicine (OPM): OPM Announces Its 2026 Half-Year Financial Results and Provides an Update on Its Clinical Developments and Financial Position561OPM-201: secured funding from the Michael J. Fox Foundation to support the development of the LARKIN program in Parkinson's disease OPM-101: continued preparation for the REVERT Phase 1b/2a...
► Artikel lesen
08.10.Oncodesign Precision Medicine Advances OPM-201 Toward Phase 1b Parkinson's Disease Trial3
07.10.Oncodesign Precision Medicine: OPM Achieved Several Major Scientific and Regulatory Milestones as Part of the LARKIN Program, Supported With Funding By The Michael J. Fox Foundation for Parkinson's Research (MJFF)618MJFF confirms its support to the program with the payment of an additional funding tranche Successful micronization of the active pharmaceutical ingredient and manufacturing of the first...
► Artikel lesen
30.04.Oncodesign Precision Medicine (OPM): OPM Announces Its 2025 Annual Results and Provides an Update on Its Clinical Developments800Continued development of OPM-101 with Phase 1 clinical validation and approval to initiate the REVERT study (Phase 1b/2a in oncology) Significant progress with OPM-201: independent validation...
► Artikel lesen
03.03.Oncodesign Precision Medicine Receives Support from The Michael J. Fox Foundation to Advance Development of LRRK2 Inhibitor OPM-201 for Parkinson's Disease806The grant will support the preparation of clinical Drug Product for Phase 1b and start of Phase 2 in people with Parkinson's disease and the execution of long-term toxicology study including...
► Artikel lesen
ONCODESIGN PRECISION MEDICINE Aktie jetzt für 0€ handeln
08.01.Oncodesign Precision Medicine and Ksilink Join Forces to Test the Nanocyclix Chemical Library in Cell Models Derived From Patients With Serious Central Nervous System Diseases538Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker symbol: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant...
► Artikel lesen
29.12.25Oncodesign Precision Medicine and Navigo Proteins Announce the End of Their Collaboration in the Development of Radiotheranostics495Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic...
► Artikel lesen
7 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1